Expert Interview
A second look at the potential use of Merck's gefapixant in anticipation of the FDA Adcom review which was previously rejected by the FDA
Ticker(s): MRKInstitution: Private Practice
-
Private practice pulmonologist in a large suburban setting
-
Currently treats 20 patients with IPF and 5-10 with avium complex lung disease
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
